Variants of the NK1 fragment of hepatocyte growth factor/scatter factor (HGF/SF) and their use
View Patent ↗Variants of the NK1 fragment of the polypeptide growth factor HGF/SF which act as agonists of the MET receptor and their use are disclosed. The agonists comprise at least one substitution at positions equivalent to 132, 134, 170 and 181 of full length HGF/SF (SEQ ID NO:2) and these substitutions provide variants which show scatter factor activity and induce DNA synthesis. In vivo, the variants provide protection from liver damage in a model of acute liver failure.
1. A method for stimulating the growth of a cell which expresses the MET receptor, said method comprising bringing a polypeptide into contact with said cell, the polypeptide comprising SEQ ID NO:1, wherein the amino acid of at least one of positions 105, 107, 143 and 154 is substituted.
2. A method of treatment of a patient having a disease condition which requires stimulation of cell growth of a cell which expresses the MET receptor, said method comprising administering to a patient an effective amount of a polypeptide comprising SEQ ID NO:1, wherein the amino acid of at least one of positions 105, 107, 143 and 154 is substituted.
3. A method of treatment or prevention of liver damage in a subject who has ingested N-acetyl-p-aminophenol, the method comprising administering to the subject an effective amount of a polypeptide selected from an NK1 polypeptide or a polypeptide comprising SEQ ID NO:1, wherein the amino acid of at least one of positions 105, 107, 143 and 154 is substituted.
4. A method of treatment or reducing the risk of liver failure, the method comprising administering to the subject an effective amount of a polypeptide selected from an NK1 polypeptide or a polypeptide comprising SEQ ID NO:1, wherein the amino acid of at least one of positions 105, 107, 143 and 154 is substituted.
5. A method for stimulating the growth of a cell which expresses the MET receptor, said method comprising bringing a polypeptide into contact with said cell, the polypeptide comprising a fragment of SEQ ID NO:2, said fragment comprising amino acids 132-181, wherein the amino acid of at least one of positions 132, 134, 170 or 181 is substituted, and said fragment exhibits heparin-dependent dimerization and is a MET receptor agonist.
6. A method of treatment of a patient having a disease condition which requires stimulation of cell growth of a cell which expresses the MET receptor, said method comprising administering to a patient an effective amount of a polypeptide comprising a fragment of SEQ ID NO:2, said fragment comprising amino acids 132-181, wherein the amino acid of at least one of positions 132, 134, 170 or 181 is substituted, and said fragment exhibits heparin-dependent dimerization and is a MET receptor agonist.
7. A method of treatment or prevention of liver damage in a subject who has ingested N-acetyl-p-aminophenol, the method comprising administering to the subject an effective amount of a polypeptide comprising a fragment of SEQ ID NO:2, said fragment comprising amino acids 132-181, wherein the amino acid of at least one of positions 132, 134, 170 or 181 is substituted, and said fragment exhibits heparin-dependent dimerization and is a MET receptor agonist.
8. A method of treatment or reducing the risk of liver failure, the method comprising administering to the subject an effective amount of a polypeptide comprising a fragment of SEQ ID NO:2, said fragment comprising amino acids 132-181, wherein the amino acid of at least one of positions 132, 134, 170 or 181 is substituted, and said fragment exhibits heparin-dependent dimerization and is a MET receptor agonist.